TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01736189
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pre-filled syringe, administered by subcutaneous injection
Study: NCT04210427
Drug: Polyethylene Glycol 3350
Normalized name: Polyethylene Glycol 3350
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will undergo intervention with taking polyethylene glycol (PEG) or Miralax (brand name) 17 grams once daily for total of 2 weeks.
Study: NCT03780361
Drug: Aflibercept Injection
Normalized name: aflibercept Injection
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Total 5 times of monthly intravitreal aflibercept injections will be done.
Study: NCT03240822
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05461833
Drug: OTILONII BROMIDUM
Normalized name: otilonium bromide
DrugBank: Otilonium (DB13500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTILONII BROMIDUM , oral, 40 mg TID, 1 months of treatment
Study: NCT00566540
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive Cisplatin (30 mg/m2 i.v.) daily x 3 days in week 1.
Study: NCT00566540
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive Paclitaxel (45 mg/m2i.v.) infusion over 3 hours during weeks 7,8,9,10
Study: NCT00964262
Drug: SR Exenatide (PT302)
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg, 1.0 mg, 2.0 mg and 4.0 mg dosage(dose escalation), single subcutaneous injection
Study: NCT01832857
Drug: CPI-613
Normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is the maximum tolerated dosing \[MTD\]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
Study: NCT00308243
Drug: Sodium Pyruvate in 0.9% Sodium Chloride Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03748979
Drug: TAK-925
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-925
Study: NCT00389974
Drug: sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT01294397
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered by subcutaneous injection once a week
Study: NCT01294397
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT01541852
Drug: Losmapimod
Normalized name: Losmapimod
DrugBank: Losmapimod (DB12270)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of Losmapimod 7.5mg twice daily
Study: NCT04916899
Drug: Rifampicin/ Isoniazid/ Pyrazinamide/ Ethambutol
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Form: Tablets Dosage: 150 mg / 75 mg / 400 mg / 300 mg Adminstration way: Oral
Study: NCT01152541
Drug: Riboflavin/Dextran
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of riboflavin/dextran every 2 minutes for the duration of UV exposure
Study: NCT01152541
Drug: Hypotonic Riboflavin
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of hypotonic riboflavin every 2 minutes for the duration of UV exposure.
Study: NCT02806362
Drug: Ombitasvir/paritaprevir/ritonavir
Normalized name: ombitasvir/paritaprevir/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet
Study: NCT02393742
Drug: Sodium nitrite
Normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01852461
Drug: Beractant
Normalized name: Beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beractant;both initial and subsequent dosing is 100 mg/kg (4 mL/kg), which may be given every 6 hours up to four total doses
Study: NCT01852461
Drug: Poractant alfa
Normalized name: Poractant alfa
DrugBank: Poractant alfa (DB09113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: porcine lung extract, initial dosing is 200 mg/kg (2.5 mL/kg) and repeated dosing is given at 100 mg/kg (1.25 mL/kg) every 12 hours, up to maximum of two additional doses when indicated
Study: NCT02132832
Drug: Buspirone
Normalized name: Buspirone
DrugBank: Buspirone (DB00490)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buspirone is an anxiolytic compound marked by modulation of both 5-HT1A and D3 receptors. Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.
Study: NCT00919191
Drug: Adapalene and Benzoyl peroxide
Normalized name: Adapalene and Benzoyl Peroxide Gel
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene .1% and Benzoyl peroxide 2.5%
Study: NCT00541853
Drug: Candesartan
Normalized name: Candesartan
DrugBank: Candesartan (DB13919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan upto 8mg
Study: NCT00541853
Drug: Candesartan and Cilnidipine
Normalized name: candesartan and diuretics
DrugBank: Cilnidipine (DB09232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan upto 8mg per day and Cilnidipine upto 20mg per day
Study: NCT00385450
Drug: Nelfinavir/placebo
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1250mg/twice each day/four days.
Study: NCT00541853
Drug: Candesartan plus non-CCB agents
DrugBank: Candesartan (DB13919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan upto 8mg per day and other antihypertensive drugs except CCB and ACEI
Study: NCT03822975
Drug: Bivalirudin
Normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bivaliruding 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 2-4 hours after PCI. It is recommended that ACT be monitored 5 minutes after the first administration, and if ACT is \<225 s (Hemotec method), intravenous injection of 0.35 mg/kg of bivalirudin should be administered, and the ACT re-checked to ensure it is \>225 seconds.
Study: NCT03822975
Drug: unfractionated Heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin 70 U/kg is started before coronary angiography. ACT is monitored 5 min after the first administration, and if the ACT \<225 s (Hemotec method), an intravenous injection of 1000 U of heparin is administered, and the ACT re-checked to ensure it is \>225 seconds.
Study: NCT03812029
Drug: Vonafexor
Normalized name: Vonafexor
DrugBank: Vonafexor (DB18782)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT01132820
Drug: Cediranib Maleate
Normalized name: maleate
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00677534
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50,000 Units PO Twice weekly for 8 weeks
Study: NCT00296257
Drug: SMP-114
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03733353
Drug: EDP1815
Normalized name: EDP1815
DrugBank: EDP1815 (DB16486)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP1815 is an orally administered monoclonal microbial
Study: NCT01821404
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules including 80 mg of atorvastatin
Study: NCT02228902
Drug: Ferrous fumarate
Normalized name: Ferrous Fumarate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one group receives ferrous fumarate (12 patients) and one group (12 patients) receives ferrous gluconate
Study: NCT02228902
Drug: Ferrous gluconate
Normalized name: Ferrous Gluconate
DrugBank: Ferrous gluconate (DB14488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One group receives ferrous fumarate and one group receives ferrous fumarate.
Study: NCT04142060
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be dispensed with oral enzalutamide 160 mg (four 40 mg capsules) as a self-administered single oral daily dose, continuously.
Study: NCT00332462
Drug: Cyclosporine (Sandimmun® i.v.)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (Sandimmun® i.v.) intravenous given 2 times daily as an infusion over four hours staring at a dose of 2 X 200 mg/day for 7 days. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
Study: NCT00332462
Drug: Cyclosporine (Sandimmun® Optoral)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandimmun® Optoral microemulsion oral capsule twice daily starting at an initial daily dose of 8-12 mg/kg/day. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
Study: NCT00039663
Drug: Gemfibrozil
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00039663
Drug: Rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01527747
Drug: Saxagliptin
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg daily
Study: NCT00863681
Drug: Riociguat (BAY63-2521)
Normalized name: Riociguat
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BAY63-2521: 1mg tid -2.5 mg tid oral until end of study
Study: NCT02764268
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01148342
Drug: MDMA
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01148342
Drug: (+/-)3,4-methylenedioxymethamphetamine Hydrochloride, MDMA HCI Capsules
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0, 1.0 \&amp; 1.6 mg/kg
Study: NCT01236638
Drug: Momelotinib
Normalized name: MOMELOTINIB
DrugBank: Momelotinib (DB11763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will continue receiving the same doses as assigned during the CCL09101 protocol; up to 400 mg once per day (QD). CYT387 will be administered orally as a single daily dose (at least 20 and no more than 28 hours apart, preferably in a fasted state at least two hours before and one hour after a meal), except for patients on the twice daily (BID) dosing regime (150 mg BID).
Study: NCT00338962
Drug: paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: paroxetine (40mg/day)
Study: NCT00338962
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg per day
Study: NCT00175643
Drug: imiquimod
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02207855
Drug: Chloroprocaine
Normalized name: Chloroprocaine
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01359787
Drug: Mapracorat
Normalized name: Mapracorat
DrugBank: Mapracorat (DB12041)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily topical application
Study: NCT01359787
Drug: Vehicle without active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily topical application
Study: NCT01832415
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Observation of bevacizumab administration in first line ovarian cancer treatment
Study: NCT03815812
Drug: IBI306
Normalized name: Immunoglobulin igg2, anti-(human proprotein convertase subtilisin/kexin type 9) (human monoclonal ibi306 .gamma.2-chain), disulfide with human monoclonal ibi306 .kappa.-chain, dimer
DrugBank: Tafolecimab (DB16336)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W
Study: NCT01860326
Drug: Alisporivir
Normalized name: Alisporivir
DrugBank: Alisporivir (DB12139)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules supplied as open labeled bulk medication in 10-unit blister packages
Study: NCT02537223
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04432402
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide: 10mg、15mg、20mg、25mg qd PO day 1-7, Rituximab: 375 mg/m2 IV day0, Gemcitabine :1g/m2 IV day 1, oxaliplatin 100mg/m2 IV day1 (every 14 days as a cycle)
Study: NCT02406261
Drug: Lanabecestat
Normalized name: Lanabecestat
DrugBank: Lanabecestat (DB14814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg lanabecestat will be administered orally as 1 × 50-mg tablet
Study: NCT03225326
Drug: Computer controlled 4% articaine delivery by Anaeject
DrugBank: Articaine (DB09009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by computer controlled local anesthetic delivery system (Anaeject)
Study: NCT03225326
Drug: Conventional 4% articaine delivery by carpule syringe
DrugBank: Articaine (DB09009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by conventional syringe (carpule syringe).
Study: NCT02406261
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mcg midazolam will be administered orally as 0.25 mL of 2-mg/mL syrup
Study: NCT02406261
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mcg midazolam will be administered intravenous (IV) as 0.25 mL of 1-mg/mL injection solution
Study: NCT02406261
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg donepezil will be administered orally as 1 × 5-mg tablet
Study: NCT01165840
Drug: Dapsone
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg PO x 1 dose
Study: NCT00199030
Drug: Alemtuzumab (MabCampath)
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00199030
Drug: Cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01280240
Drug: Monofer(R)
Normalized name: Monoferric
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus injection given over app. 2 minutes only once
Study: NCT02797080
Drug: interferon γ-1b
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTIMMUNE® will be administered three times per week by subcutaneous injection. The initial dose will be individualized for each participant and will be determined by the investigator, provided that the initial dose does not exceed the maximum tolerated dose in HZNP-ACT-302 (NCT02593773). The investigator may subsequently adjust the dose for any participant if deemed clinically appropriate, provided that the dose does not exceed 100 μg/m².
Study: NCT02650895
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.9% sodium chloride
Study: NCT00230321
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During the induction phase, the investigational agent DARBEPOETIN ALFA will be initiated at a dose of 4.5 ug/kg/week subcutaneously.If patients do not achieve a major erythroid response by 6 weeks, the dose of DARBEPOETIN ALFA will be doubled to 9.0 ug/kg/week.
Study: NCT00001197
Drug: Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00832338
Drug: Docetaxel with Cytoxan
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m² plus cytoxan 600 mg/m² every 3 weeks for 6 cycles.
Study: NCT02097303
Drug: Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radium Ra 223 dichloride - A targeted alpha particle-emitting pharmaceutical (a radiopharmaceutical drug) is a ready-to-use solution for intravenous injection containing the drug substance radium dichloride. The active moiety is the alpha particle emitting nuclide Ra-223, present as a divalent cation (223Ra2+) and Abiraterone Acetate - A CYP17 inhibitor, indicated in combination with prednisone for the treatment of subjects with metastatic castration-resistant prostate cancer. Administration of Abiraterone Acetate may result in mineralocorticoid-related adverse events (AEs), due to CYP17 inhibition. Therefore, Abiraterone Acetate is administered in combination with Prednisone to reduce the frequency of these AEs.
Study: NCT01777165
Drug: ABT-719
Normalized name: ABT-925
DrugBank: ABT-751 (DB12254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 arm of ABT-719 higher dose, 1 arm of ABT-719 intermediate dose, and 1 arm ABT-719 lower dose
Study: NCT00832338
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 4 mg BID PO for 3 consecutive days starting 12-24 hours prior to each dose of docetaxel.
Study: NCT05506865
Drug: Indacaterol
Normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indacaterol, one inhales capsule, 150 mcgr, by dry powder dispositive
Study: NCT05506865
Drug: Tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 mcgr, one inhaled capsule, by dry powder inhaler handihaler
Study: NCT02398669
Drug: Lorcaserin hydrochloride
Normalized name: Lorcaserin Hydrochloride
DrugBank: Lorcaserin (DB04871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single 10 mg dose of oral tablet formulation of lorcaserin hydrochloride will be administered with 240 mL of water.
Study: NCT01948362
Drug: Alpha cyclodextrin
Normalized name: alpha cyclodextrin
DrugBank: Cyclo(his-pro) (DB02414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control
Study: NCT00152490
Drug: Certolizumab Pegol (CDP870)
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02222896
Drug: Chlorhexidine Gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2% CHG solution on cloth
Study: NCT02222896
Drug: DynaHex-2
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2% CHG solution
Study: NCT00601718
Drug: vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00601718
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00601718
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00601718
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02744248
Drug: IOP Injection
Normalized name: AVOBENZONE 1.25 g in 50 mL / HOMOSALATE 4.5 g in 50 mL / OCTISALATE 2.25 g in 50 mL / OCTOCRYLENE 4.5 g in 50 mL TOPICAL CREAM [IOPE UV DEFENSE SUN PROTECTOR]
DrugBank: Avobenzone (DB09495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IOP Injection 20 mg Fe/ml, intravenous injection
Study: NCT02597712
Drug: YF476
Normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gastrin receptor antagonist
Study: NCT03335436
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive Gabapentin 600 mg by mouth one hour prior to scheduled cesarean delivery and 400 mg by mouth every 8 hours post delivery
Study: NCT00053872
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00053872
Drug: lomustine
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00053872
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03490838
Drug: 177Lu-PSMA-R2
Normalized name: 177Lu-PSMA-617
DrugBank: Lutetium Lu-177 vipivotide tetraxetan (DB16778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: radio-ligand therapy
Study: NCT01441635
Drug: Elagolix
Normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elagolix tablets
Study: NCT01441635
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone 200 mg administered during the last 12 days of the 28-day menstrual cycle
Study: NCT02799641
Drug: Diazepam
Normalized name: Diazepam
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg Diazepam
Study: NCT02799641
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 ml of 2% lidocaine
Study: NCT02078128
Drug: oral sugar powder
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg, oral every day until wound healed completes or unacceptable toxicity develops.
Study: NCT04760262
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane %2-3 for general anesthesia maintenance, BIS values were arranged 40-60 until the end of operation, In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased